NO20062703L - Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel - Google Patents

Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel

Info

Publication number
NO20062703L
NO20062703L NO20062703A NO20062703A NO20062703L NO 20062703 L NO20062703 L NO 20062703L NO 20062703 A NO20062703 A NO 20062703A NO 20062703 A NO20062703 A NO 20062703A NO 20062703 L NO20062703 L NO 20062703L
Authority
NO
Norway
Prior art keywords
useful
preparation
quinazoline derivative
antiangiogenic agents
maleate salts
Prior art date
Application number
NO20062703A
Other languages
English (en)
Other versions
NO336613B1 (no
Inventor
James Mccabe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30776508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062703(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20062703L publication Critical patent/NO20062703L/no
Publication of NO336613B1 publication Critical patent/NO336613B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse omhandler AZD2171 maleatsalt, spesielle krystallinske former av AZD2171 maleatsalt, fremgangsmåter for fremstilling av dem, farmasøytiske preparater inneholdende dem som aktiv bestanddel, anvendelse av dem ved fremstillingen av medikamenter for anvendelse ved fremstillingen av antiangiogeniske og/eller vaskulære permeabilitetsreduserende effekter hos varmblodige dyr så som mennesker og anvendelse av dem ved metoder for behandlingen av sykdomstilstander forbundet med angiogenese og/eller øket vaskulær permeabilitet. AZD 2171
NO20062703A 2003-12-24 2006-06-12 Maleatsalter av 4-((4-fluor-2-metyl-1H-indol-5-yl)oksy)-6-metoksy-7-(3-(pyrrolidin-1-yl)propoksy)kinazolin i krystallinsk form, fremgangsmåte for fremstilling av slike, farmasøytisk preparat omfattende slike samt anvendelse av slike for fremstilling av et medikament for behandling av sykdom NO336613B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0330002.7A GB0330002D0 (en) 2003-12-24 2003-12-24 Quinazoline derivatives
PCT/GB2004/005359 WO2005061488A1 (en) 2003-12-24 2004-12-18 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

Publications (2)

Publication Number Publication Date
NO20062703L true NO20062703L (no) 2006-07-20
NO336613B1 NO336613B1 (no) 2015-10-12

Family

ID=30776508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062703A NO336613B1 (no) 2003-12-24 2006-06-12 Maleatsalter av 4-((4-fluor-2-metyl-1H-indol-5-yl)oksy)-6-metoksy-7-(3-(pyrrolidin-1-yl)propoksy)kinazolin i krystallinsk form, fremgangsmåte for fremstilling av slike, farmasøytisk preparat omfattende slike samt anvendelse av slike for fremstilling av et medikament for behandling av sykdom

Country Status (33)

Country Link
US (6) US20070129387A1 (no)
EP (1) EP1699782B1 (no)
JP (2) JP5009628B2 (no)
KR (1) KR101240872B1 (no)
CN (2) CN102153543B (no)
AR (2) AR046993A1 (no)
AT (1) ATE471936T1 (no)
AU (1) AU2004303590B2 (no)
BR (1) BRPI0417958B8 (no)
CA (1) CA2548662C (no)
CY (1) CY1110730T1 (no)
DE (1) DE602004027833D1 (no)
DK (1) DK1699782T3 (no)
ES (1) ES2345776T3 (no)
GB (1) GB0330002D0 (no)
HK (1) HK1095325A1 (no)
HR (1) HRP20100455T1 (no)
IL (1) IL176308A (no)
MX (1) MXPA06007191A (no)
MY (1) MY145143A (no)
NO (1) NO336613B1 (no)
NZ (1) NZ547547A (no)
PL (1) PL1699782T3 (no)
PT (1) PT1699782E (no)
RS (1) RS51387B (no)
RU (1) RU2425043C2 (no)
SA (1) SA05250464B1 (no)
SI (1) SI1699782T1 (no)
TW (1) TWI339119B (no)
UA (1) UA91332C2 (no)
UY (1) UY28702A1 (no)
WO (1) WO2005061488A1 (no)
ZA (1) ZA200605225B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
AU2003202094B2 (en) * 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
BRPI0620118A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de azd2171 ou de um sal farmaceuticamente aceitável do mesmo e de permetrexed, composição farmacêutica, kit, e, método para a produção de um efeito de redução da permeabilidade antiangiogênica, e/ou vascular em um animal de sangue quente
US7851623B2 (en) 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
EA020764B1 (ru) * 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
NZ598693A (en) * 2009-09-25 2013-10-25 Kyorin Seiyaku Kk Maleic acid salt and crystal thereof
WO2013188279A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing cediranib
US9007866B2 (en) 2013-04-23 2015-04-14 Tessera Inc. Retention optimized memory device using predictive data inversion
CA3109285A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
CN105461698A (zh) * 2014-09-12 2016-04-06 杭州普晒医药科技有限公司 西地尼布盐及其晶型、以及其制备方法和药物组合物
WO2017035170A1 (en) * 2015-08-24 2017-03-02 Pliva Hrvatska D.O.O Solid state forms of cediranib maleate
AU2017221268B2 (en) 2016-02-15 2024-02-15 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
US10255725B2 (en) * 2016-11-16 2019-04-09 Disney Enterprises, Inc. Augmented reality interactive experience
CN110817898B (zh) * 2018-08-13 2021-09-03 中国科学院大连化学物理研究所 一种具有ats骨架结构的磷酸硅铝分子筛及其制备方法和应用
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU686843B2 (en) 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
EP1005470B1 (en) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
PL199802B1 (pl) * 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1226136B1 (en) 1999-10-19 2004-12-29 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1676845B1 (en) * 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US20030118078A1 (en) * 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
AU2003202094B2 (en) 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
DE602004027833D1 (de) 2010-08-05
US9556151B2 (en) 2017-01-31
CA2548662C (en) 2013-09-03
BRPI0417958B8 (pt) 2021-05-25
NO336613B1 (no) 2015-10-12
US20070129387A1 (en) 2007-06-07
NZ547547A (en) 2009-08-28
US20100298357A1 (en) 2010-11-25
JP5009628B2 (ja) 2012-08-22
CN1898232B (zh) 2011-08-17
EP1699782A1 (en) 2006-09-13
HK1095325A1 (en) 2007-05-04
UY28702A1 (es) 2005-07-29
JP2011088936A (ja) 2011-05-06
DK1699782T3 (da) 2010-08-30
JP2007517008A (ja) 2007-06-28
US8859570B2 (en) 2014-10-14
CN1898232A (zh) 2007-01-17
TWI339119B (en) 2011-03-21
BRPI0417958B1 (pt) 2019-02-05
IL176308A0 (en) 2006-10-05
RU2425043C2 (ru) 2011-07-27
SA05250464B1 (ar) 2008-08-27
CY1110730T1 (el) 2015-06-10
RS51387B (en) 2011-02-28
RU2006126782A (ru) 2008-01-27
WO2005061488A1 (en) 2005-07-07
KR20060127899A (ko) 2006-12-13
CN102153543A (zh) 2011-08-17
AU2004303590B2 (en) 2009-07-30
PL1699782T3 (pl) 2010-10-29
SI1699782T1 (sl) 2010-09-30
PT1699782E (pt) 2010-08-04
BRPI0417958A (pt) 2007-03-27
AU2004303590A1 (en) 2005-07-07
TW200524593A (en) 2005-08-01
HRP20100455T1 (hr) 2010-09-30
GB0330002D0 (en) 2004-01-28
EP1699782B1 (en) 2010-06-23
US20190375730A1 (en) 2019-12-12
ATE471936T1 (de) 2010-07-15
AR104979A2 (es) 2017-08-30
ZA200605225B (en) 2007-05-30
IL176308A (en) 2013-03-24
MY145143A (en) 2011-12-30
CA2548662A1 (en) 2005-07-07
CN102153543B (zh) 2013-01-02
US20150025091A1 (en) 2015-01-22
AR046993A1 (es) 2006-01-04
UA91332C2 (uk) 2010-07-26
US20180170913A1 (en) 2018-06-21
MXPA06007191A (es) 2006-08-23
US9890140B2 (en) 2018-02-13
KR101240872B1 (ko) 2013-03-07
ES2345776T3 (es) 2010-10-01
US20170000791A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
NO20062703L (no) Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
WO2005000232A3 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
NO20045301L (no) Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav.
NO20052739L (no) CCR5-antagonister som medikamenter
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
UY28778A1 (es) Derivados de pirrol como inhibidores del factor xa
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
NO20050514L (no) Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409881A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
NO20054360L (no) Nye oxazolderivater, deres fremstilling og anvendelse som farmasotiske preparater
DZ3459A1 (fr) Derives de 2h-1-benzopyran, procedes de preparation de ces derniers et compositions pharmaceutiques dans lesquels ils entrent.
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.